Filter

Refine by collections

Refine by date

—
  • Print
  • Save

Search Results

You are looking at 1 - 10 of 29 items for :

  • immune checkpoint inhibitors x
Clear All
Ruth Percik Institute of Endocrinology, Diabetes and Metabolism, Sheba Medical Centre, Ramat Gan, Israel

Search for other papers by Ruth Percik in
Google Scholar
PubMed Close
,
Sherwin Criseno Department of Endocrinology, University Hospital Birmingham, Birmingham, UK

Search for other papers by Sherwin Criseno in
Google Scholar
PubMed Close
,
Safwaan Adam Department of Endocrinology, The Christie NHS Foundation Trust, Manchester, UK

Search for other papers by Safwaan Adam in
Google Scholar
PubMed Close
,
Kate Young Royal Marsden Hospital, London, UK

Search for other papers by Kate Young in
Google Scholar
PubMed Close
, and
Daniel L Morganstein Department of Endocrinology, Chelsea and Westminster Hospital, London, UK
Royal Marsden Hospital, London, UK

Search for other papers by Daniel L Morganstein in
Google Scholar
PubMed Close

Introduction Endocrinopathies are amongst the most frequent adverse events of immune checkpoint inhibitors (ICPIs). In common with all other side effects of systemic anticancer treatment, they are currently reported according to the Common

Article Type:
Review Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-22-0513
Volume/Issue:
Volume 12: Issue 5
Open access
Hanna Karhapää Medical Faculty, University of Helsinki, Helsinki, Finland
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland

Search for other papers by Hanna Karhapää in
Google Scholar
PubMed Close
,
Siru Mäkelä Medical Faculty, University of Helsinki, Helsinki, Finland
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland

Search for other papers by Siru Mäkelä in
Google Scholar
PubMed Close
,
Hanna Laurén Medical Faculty, University of Helsinki, Helsinki, Finland
Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

Search for other papers by Hanna Laurén in
Google Scholar
PubMed Close
,
Marjut Jaakkola Medical Faculty, University of Helsinki, Helsinki, Finland
Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

Search for other papers by Marjut Jaakkola in
Google Scholar
PubMed Close
,
Camilla Schalin-Jäntti Medical Faculty, University of Helsinki, Helsinki, Finland
Endocrinology, Abdominal Centre, University of Helsinki and HUS, Helsinki, Finland

Search for other papers by Camilla Schalin-Jäntti in
Google Scholar
PubMed Close
, and
Micaela Hernberg Medical Faculty, University of Helsinki, Helsinki, Finland
Department of Oncology, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland

Search for other papers by Micaela Hernberg in
Google Scholar
PubMed Close

Introduction Treatment outcomes of metastatic melanoma significantly improved after the introduction of immune checkpoint inhibitors (ICIs). By binding to their ligands, they prevent inhibitory signals, enhance the proliferation of T

Article Type:
Research Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-21-0562
Volume/Issue:
Volume 11: Issue 2
Open access
Maria Stelmachowska-Banaś Department of Endocrinology, The Centre of Postgraduate Medical Education, Warsaw, Polska, Poland

Search for other papers by Maria Stelmachowska-Banaś in
Google Scholar
PubMed Close
and
Izabella Czajka-Oraniec Department of Endocrinology, The Centre of Postgraduate Medical Education, Warsaw, Polska, Poland

Search for other papers by Izabella Czajka-Oraniec in
Google Scholar
PubMed Close

Introduction Over the past several years, immunotherapy with immune checkpoint inhibitors (ICIs) has become an effective treatment of many malignancies. Immune checkpoints are molecules on the surface of immune cells involved in the regulation

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-20-0342
Volume/Issue:
Volume 9: Issue 10
Open access
Bliss Anderson Department of Endocrinology, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK

Search for other papers by Bliss Anderson in
Google Scholar
PubMed Close
and
Daniel L Morganstein Department of Endocrinology, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK

Search for other papers by Daniel L Morganstein in
Google Scholar
PubMed Close

Introduction Immunotherapy with immune checkpoint inhibitors (CPI’s) has been revolutionising the management of advanced malignancies with their success in improving overall patient survival ( 1 , 2 ). CPI’s are antibodies that block T

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-20-0489
Volume/Issue:
Volume 10: Issue 3
Open access
C E Higham Department of Endocrinology, Christie Hospital NHS Foundation Trust, Manchester, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK

Search for other papers by C E Higham in
Google Scholar
PubMed Close
,
A Olsson-Brown The Clatterbridge Cancer Centre, Bebbington, Wirral, UK
The University of Liverpool, Brownlow Hill, Liverpool, UK

Search for other papers by A Olsson-Brown in
Google Scholar
PubMed Close
,
P Carroll Department of Endocrinology, Guy’s & St. Thomas’ NHS Foundation Trust, London, UK

Search for other papers by P Carroll in
Google Scholar
PubMed Close
,
T Cooksley Department of Acute Medicine, UHSM and Christie Hospital NHS Foundation Trust, Manchester, UK

Search for other papers by T Cooksley in
Google Scholar
PubMed Close
,
J Larkin Skin Unit, Royal Marsden Hospital, London, UK

Search for other papers by J Larkin in
Google Scholar
PubMed Close
,
P Lorigan Department of Medical Oncology, Christie Hospital NHS Foundation Trust, Manchester, UK

Search for other papers by P Lorigan in
Google Scholar
PubMed Close
,
D Morganstein Department of Endocrinology, Chelsea and Westminster Hospital, London, UK

Search for other papers by D Morganstein in
Google Scholar
PubMed Close
,
P J Trainer Department of Endocrinology, Christie Hospital NHS Foundation Trust, Manchester, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK

Search for other papers by P J Trainer in
Google Scholar
PubMed Close
, and
the Society for Endocrinology Clinical Committee The Society for Endocrinology, Starling House, 1600 Bristol Parkway North, Bristol, UK

Search for other papers by the Society for Endocrinology Clinical Committee in
Google Scholar
PubMed Close

by immune-mediated adverse effects particularly with combination treatment ( 3 , 4 , 5 , 6 ). Immune-mediated endocrinopathies as a consequence of treatment with checkpoint inhibitors include hypophysitis, adrenalitis, thyroiditis and diabetes

Article Type:
Other
DOI:
https://doi.org/10.1530/EC-18-0068
Volume/Issue:
Volume 7: Issue 7
Open access
Anna Olsson-Brown Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
The Clatterbridge Cancer Centre, Wirral, UK

Search for other papers by Anna Olsson-Brown in
Google Scholar
PubMed Close
,
Rosemary Lord The Clatterbridge Cancer Centre, Wirral, UK

Search for other papers by Rosemary Lord in
Google Scholar
PubMed Close
,
Joseph Sacco The Clatterbridge Cancer Centre, Wirral, UK
Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK

Search for other papers by Joseph Sacco in
Google Scholar
PubMed Close
,
Jonathan Wagg Roche Innovation Center, Basel, Switzerland

Search for other papers by Jonathan Wagg in
Google Scholar
PubMed Close
,
Mark Coles Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK

Search for other papers by Mark Coles in
Google Scholar
PubMed Close
, and
Munir Pirmohamed Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK

Search for other papers by Munir Pirmohamed in
Google Scholar
PubMed Close

Introduction Oncological immune checkpoint inhibitors (ICI) are transforming oncological practice ( 1 , 2 , 3 ). The first ICI, ipilimumab (Yervoy®), a CTLA-4 inhibitor, was used exclusively in metastatic malignant melanoma post

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-19-0473
Volume/Issue:
Volume 9: Issue 4
Open access
Jaafar Jaafar Division of Endocrinology and Diabetology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

Search for other papers by Jaafar Jaafar in
Google Scholar
PubMed Close
,
Eugenio Fernandez Department of Oncology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

Search for other papers by Eugenio Fernandez in
Google Scholar
PubMed Close
,
Heba Alwan Division of Endocrinology and Diabetology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

Search for other papers by Heba Alwan in
Google Scholar
PubMed Close
, and
Jacques Philippe Division of Endocrinology and Diabetology, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland

Search for other papers by Jacques Philippe in
Google Scholar
PubMed Close

Introduction A paradigm shift in the landscape of cancer treatment is in progress. Immune checkpoint inhibitors (ICIs) have emerged as new arms in the panoply of antitumor therapy. Nowadays, the interest in ICIs, such as programmed cell death

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-18-0079
Volume/Issue:
Volume 7: Issue 5
Open access
Tiina Vesterinen HUSLAB, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland

Search for other papers by Tiina Vesterinen in
Google Scholar
PubMed Close
,
Teijo Kuopio Department of Biological and Environmental Science, University of Jyväskylä and Department of Pathology, Central Finland Health Care District, Jyväskylä, Finland

Search for other papers by Teijo Kuopio in
Google Scholar
PubMed Close
,
Maarit Ahtiainen Department of Education and Research, Central Finland Central Hospital, Jyväskylä, Finland

Search for other papers by Maarit Ahtiainen in
Google Scholar
PubMed Close
,
Aija Knuuttila Department of Pulmonary Medicine, Heart and Lung Center, and Cancer Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

Search for other papers by Aija Knuuttila in
Google Scholar
PubMed Close
,
Harri Mustonen Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

Search for other papers by Harri Mustonen in
Google Scholar
PubMed Close
,
Kaisa Salmenkivi HUSLAB, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

Search for other papers by Kaisa Salmenkivi in
Google Scholar
PubMed Close
,
Johanna Arola HUSLAB, Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

Search for other papers by Johanna Arola in
Google Scholar
PubMed Close
, and
Caj Haglund Department of Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Translational Cancer Medicine Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland

Search for other papers by Caj Haglund in
Google Scholar
PubMed Close

patients. However, as only a limited number of patients benefited from the treatment, for example combination therapies are needed to potentiate the efficacy of immune checkpoint inhibitors. At the moment, PD-L1 expression is the best known biomarker for

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-19-0308
Volume/Issue:
Volume 8: Issue 8
Open access
Deborah Cosentini Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy

Search for other papers by Deborah Cosentini in
Google Scholar
PubMed Close
,
Salvatore Grisanti Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy

Search for other papers by Salvatore Grisanti in
Google Scholar
PubMed Close
,
Alberto Dalla Volta Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy

Search for other papers by Alberto Dalla Volta in
Google Scholar
PubMed Close
,
Marta Laganà Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy

Search for other papers by Marta Laganà in
Google Scholar
PubMed Close
,
Chiara Fiorentini Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

Search for other papers by Chiara Fiorentini in
Google Scholar
PubMed Close
,
Paola Perotti Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Orbassano, Italy

Search for other papers by Paola Perotti in
Google Scholar
PubMed Close
,
Sandra Sigala Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

Search for other papers by Sandra Sigala in
Google Scholar
PubMed Close
, and
Alfredo Berruti Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, Italy

Search for other papers by Alfredo Berruti in
Google Scholar
PubMed Close

activity and better survival for cancer patients treated with immune checkpoint inhibitors ( 17 ), was found in a minority of ACC neoplasms ( 18 ). Moreover, the majority of ACC patients has a hormone-secreting disease and glucocorticoids are known to exert

Article Type:
Editorial
DOI:
https://doi.org/10.1530/EC-18-0398
Volume/Issue:
Volume 7: Issue 12
Open access
Xiaoya Zheng Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Search for other papers by Xiaoya Zheng in
Google Scholar
PubMed Close
,
Heng Xiao Department of Hepatobiliary Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Search for other papers by Heng Xiao in
Google Scholar
PubMed Close
,
Jian Long Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Search for other papers by Jian Long in
Google Scholar
PubMed Close
,
Qiang Wei Prevention of Disease Department, Chongqing Jiulongpo District Hospital of Traditional Chinese Medicine, Chongqing, China

Search for other papers by Qiang Wei in
Google Scholar
PubMed Close
,
Liping Liu Department of Ultrasound, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Search for other papers by Liping Liu in
Google Scholar
PubMed Close
,
Liping Zan Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Search for other papers by Liping Zan in
Google Scholar
PubMed Close
, and
Wei Ren Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China

Search for other papers by Wei Ren in
Google Scholar
PubMed Close

checkpoint inhibitors: review and management of endocrine adverse events . Oncologist 2016 21 804 – 816 . ( https://doi.org/10.1634/theoncologist.2015-0509 ) 4 Stelmachowska-Banas M Czajka-Oraniec I . Management of endocrine immune-related adverse

Article Type:
Research Article
Collections:
Thyroid
DOI:
https://doi.org/10.1530/EC-22-0065
Volume/Issue:
Volume 11: Issue 5
Open access